metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 17,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 17,5 mg
methotrexate pfizer (methotrexate wyeth) tafla 2,5 mg
pfizer aps - methotrexatum inn - tafla - 2,5 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 30 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 30 mg
ciflox (ciproxin-hydrocortison) eyrnadropar, dreifa 2 mg + 10 mg/ml
novartis healthcare a/s - ciprofloxacinum hýdróklóríð; hydrocortisonum inn - eyrnadropar, dreifa - 2 mg + 10 mg/ml
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 10 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 10 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 12,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 12,5 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 15 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 15 mg
metojectpen (metoject) stungulyf, lausn í áfylltum lyfjapenna 22,5 mg
medac gesellschaft für klinische spezialpräparate gmbh - methotrexatum inn - stungulyf, lausn í áfylltum lyfjapenna - 22,5 mg
competact
cheplapharm arzneimittel gmbh - lyfleysu, kvarta stutt og long-term - sykursýki, tegund 2 - lyf notuð við sykursýki - competact is indicated in the treatment of type 2 diabetes mellitus patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
eucreas
novartis europharm limited - vildagliptin, kvarta stutt og long-term - sykursýki, tegund 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - eucreas is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:in patients who are inadequately controlled with metformin hydrochloride alone. in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control.